Exploring the facilitators and barriers to using an online infertility risk prediction tool (FoRECAsT) for young women with breast cancer: a qualitative study protocol.
breast cancer
infertility
premenopausal
risk prediction
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
10 02 2020
10 02 2020
Historique:
entrez:
13
2
2020
pubmed:
13
2
2020
medline:
20
2
2021
Statut:
epublish
Résumé
As cancer treatments may impact on fertility, a high priority for young patients with breast cancer is access to evidence-based, personalised information for them and their healthcare providers to guide treatment and fertility-related decisions prior to cancer treatment. Current tools to predict fertility outcomes after breast cancer treatments are imprecise and do not offer individualised prediction. To address the gap, we are developing a novel personalised infertility risk prediction tool (FoRECAsT) for premenopausal patients with breast cancer that considers current reproductive status, planned chemotherapy and adjuvant endocrine therapy to determine likely post-treatment infertility. The aim of this study is to explore the feasibility of implementing this FoRECAsT tool into clinical practice by exploring the barriers and facilitators of its use among patients and healthcare providers. A cross-sectional exploratory study is being conducted using semistructured in-depth telephone interviews with 15-20 participants each from the following groups: (1) premenopausal patients with breast cancer younger than 40, diagnosed within last 5 years, (2) breast surgeons, (3) breast medical oncologists, (4) breast care nurses (5) fertility specialists and (6) fertility preservation nurses. Patients with breast cancer are being recruited from the joint Breast Service of three affiliated institutions of Victorian Comprehensive Cancer Centre in Melbourne, Australia-Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Royal Women's Hospital, and clinicians are being recruited from across Australia. Interviews are being audio recorded, transcribed verbatim and imported into qualitative data analysis software to facilitate data management and analyses. The study protocol has been approved by Melbourne Health Human Research Ethics Committee, Australia (HREC number: 2017.163). Confidentiality and privacy are maintained at every stage of the study. Findings will be disseminated through peer-reviewed scholarly and scientific journals, national and international conference presentations, social media, broadcast media, print media, internet and various community/stakeholder engagement activities.
Identifiants
pubmed: 32047016
pii: bmjopen-2019-033669
doi: 10.1136/bmjopen-2019-033669
pmc: PMC7044829
doi:
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e033669Subventions
Organisme : Medical Research Council
ID : G1100357
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N022556/1
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Curr Opin Oncol. 2017 Jul;29(4):243-252
pubmed: 28463857
Cell Death Dis. 2018 May 23;9(6):618
pubmed: 29795269
J Med Internet Res. 2014 Dec 02;16(12):e262
pubmed: 25470306
Med Decis Making. 1993 Oct-Dec;13(4):322-38
pubmed: 8246705
J Natl Cancer Inst. 2015 Aug 25;107(10):
pubmed: 26307641
J Clin Oncol. 2011 May 1;29(13):1670-7
pubmed: 21444865
Hum Reprod. 2012 May;27(5):1231-7
pubmed: 22357771
Anticancer Drugs. 2009 Jul;20(6):503-7
pubmed: 19339872
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Drug Des Devel Ther. 2015 Mar 24;9:1761-6
pubmed: 25848212
Int J Nurs Stud. 2010 Oct;47(10):1317-29
pubmed: 20580363
Cancer. 2014 Dec 1;120(23):3691-8
pubmed: 25081546
J Ovarian Res. 2015 Dec 14;8:82
pubmed: 26667243
J Clin Endocrinol Metab. 2011 May;96(5):1336-43
pubmed: 21325458
Curr Opin Crit Care. 2004 Oct;10(5):395-8
pubmed: 15385758
Eur J Cancer. 2007 Jul;43(11):1646-53
pubmed: 17512721
Fertil Steril. 2015 Mar;103(3):628-30
pubmed: 25500021
J Thorac Dis. 2014 Jun;6(6):584-8
pubmed: 24976976
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Hum Reprod. 1995 Jun;10(6):1397-402
pubmed: 7593504
Clin Breast Cancer. 2019 Feb;19(1):63-70
pubmed: 30241966
Hum Reprod. 2018 Jul 1;33(7):1281-1290
pubmed: 29912328
Eur J Cancer. 2013 Nov;49(16):3404-11
pubmed: 23968732
Pharmacoeconomics. 2002;20(4):215-24
pubmed: 11950379
Crit Rev Oncol Hematol. 2017 May;113:90-96
pubmed: 28427528
Br J Cancer. 2012 Mar 13;106(6):1053-61
pubmed: 22415294
J Clin Oncol. 2005 Feb 1;23(4):766-73
pubmed: 15681520
PLoS One. 2015 Oct 20;10(10):e0140842
pubmed: 26485568
Psychooncology. 2004 May;13(5):295-308
pubmed: 15133771
J Assist Reprod Genet. 2013 Nov;30(11):1407-13
pubmed: 23835721
J Clin Oncol. 2004 Oct 15;22(20):4174-83
pubmed: 15483028
World J Clin Oncol. 2017 Jun 10;8(3):241-248
pubmed: 28638793
J Med Internet Res. 2016 Jun 06;18(6):e145
pubmed: 27267955
Breast Cancer Res Treat. 2009 Jul;116(2):215-23
pubmed: 19390962
J Clin Oncol. 2014 Apr 10;32(11):1151-6
pubmed: 24567428
J Adolesc Young Adult Oncol. 2017 Jun;6(2):213-222
pubmed: 27906588
Psychooncology. 2018 Feb;27(2):401-409
pubmed: 28734119
Ann Oncol. 2017 Aug 1;28(8):1811-1816
pubmed: 28472240
Cancer. 2016 Jul 1;122(13):2101-9
pubmed: 27213483
Eur J Cancer. 2017 Dec;87:58-64
pubmed: 29117576
BMJ. 1995 Jul 8;311(6997):109-12
pubmed: 7613363
Reprod Biomed Online. 2014 Nov;29(5):573-80
pubmed: 25246112
Expert Rev Endocrinol Metab. 2018 May;13(3):125-136
pubmed: 30058903
Hum Reprod. 2007 Sep;22(9):2414-21
pubmed: 17636277